Is intravesical stent position a predictor of associated morbidity? by Abt, Dominik et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Is intravesical stent position a predictor of associated morbidity?
Abt, Dominik; Mordasini, Livio; Warzinek, Elisabeth; Schmid, Hans-Peter; Haile, Sarah Roberta;
Engeler, Daniel Stephan; Müllhaupt, Gautier
Abstract: PURPOSE: Temporary drainage of the upper urinary tract by use of internal ureteral stents
is a common procedure that is often associated with a variety of symptoms. The role of intravesical stent
position in associated morbidity is controversial. MATERIALS AND METHODS: The German version
of the ureteral stent symptom questionnaire (USSQ) was completed by 73 patients with an indwelling
ureteral stent the day before stent removal. Intravesical stent position was classified into 3 categories
by x-ray before stent removal. The influence of intravesical stent position on USSQ score was analyzed,
including subscores and single items. RESULTS: Intravesical stent position showed no significant influence
on associated morbidity. The median USSQ total score in all patients was 77.5 (range, 30-147). Patients
with ipsilateral stents (69.0; range, 30-122) tended to have lower total scores than did those with tangential
(86.5; range, 30-122) or contralateral (77.0; range, 31-147) stents, but the differences were not statistically
significant (p=0.35). The USSQ subscores for urinary symptoms (p=0.80), body pain (p=0.80), general
health (p=0.16), work performance (p=0.07), additional problems (p=0.81), and all of the USSQ single
items of interest in the context of stent length also did not differ significantly between the three groups.
CONCLUSIONS: Intravesical stent position did not significantly influence associated morbidity in our
study. An appropriate stent length should be chosen to avoid dislocation. However, complex calculations
of optimum stent length, time-consuming manipulations, and costly stock holding of various stent sizes
to obtain the perfect stent position do not seem worthwhile.
DOI: 10.4111/kju.2015.56.5.370
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-111027
Veröffentlichte Version
 
 
Originally published at:
Abt, Dominik; Mordasini, Livio; Warzinek, Elisabeth; Schmid, Hans-Peter; Haile, Sarah Roberta; En-
geler, Daniel Stephan; Müllhaupt, Gautier (2015). Is intravesical stent position a predictor of associated
morbidity? Korean Journal of Urology, 56(5):370-378. DOI: 10.4111/kju.2015.56.5.370
370
INTRODUCTION
Temporary drainage of  the upper urinary tract is a 
routine procedure to ensure renal function and to treat 
pain caused by ureteral obstruction. Internal ureteral stents 
offer a simple and effective method of ureteral drainage 
and avoid external devices. However, they are frequently 
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associated with a well-defined side effect profile. Irritative 
voiding symptoms were reported in 78% of patients and 
stent-related pain affecting daily activities was reported 
in more than 80% by Joshi et al. [1]. High rates of lower 
urinary tract symptoms (LUTS), flank pain, and hematuria 
are caused by irritation from the foreign body in the 
bladder and the vesicoureteric reflux that is generated, and 
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most of the side effects persist throughout the entire stent 
indwelling time [2]. 
In view of  the prevalence of  ureteral stenting and 
associated symptoms, Joshi et al. [3] made an important step 
forward by developing and validating the ureteral stent 
symptom questionnaire (USSQ), which analyzes various 
domains of  health affected by stents. Over the past 10 
years, the USSQ has become a well-accepted standard in 
the assessment of stent-associated symptoms and has been 
translated into different languages. Validated versions have 
been developed as recommended by Hutchinson et al. [4] in 
French [5], Italian [6], Korean [7], and Spanish [8]. Recently, 
a German version was developed in an analogous multistep 
process [4] and is at present being validated in a multicenter 
analysis in Regensburg and Sindelfingen-Böblingen in 
Germany, Salzburg in Austria, and in our own department 
(findings not yet published).
Several studies have investigated the reasons for and the 
treatment and prevention of morbidity caused by indwelling 
ureteral stents. Although it has been shown that alpha-
blockers [9] and antimuscarinics [10] can reduce symptoms 
caused by ureteral stents, neither the positioning of  the 
stent’s proximal end [11] nor stent diameter [12-14] seems to 
have an influence.
Findings regarding the possible effect of  intravesical 
stent position, a variable that can be easily adjusted, are 
ambiguous. Giannarini et al. [15] investigated predictors of 
morbidity in patients with ureteral stents and identified 
a distal loop location crossing the pelvic midline as a risk 
factor for urinary symptoms and body pain, impairment of 
general health and work performance, and sexual problems. 
Rane et al. [16], Al-Kandari et al. [11], and Ho et al. [17] showed 
similar results with the limitation of using questionnaires 
not specific for stent symptoms.
In contrast, Calvert et al. [18] did not find any difference 
between symptoms in a randomized trial comparing 24-
cm and multilength stents. Also, a multicenter study by 
Lingeman et al. [19] using the USSQ investigated whether 
a reduced amount of  intravesical stent material reduces 
stent-related symptoms and found no significant differences 
between different stents. Thus, in an attempt to clarify the 
influence of  the intravesical part of  indwelling ureteral 
stents on stent-related symptoms, we conducted a prospective 
survey at our institution.
MATERIALS AND METHODS
The study was conducted according to the Declaration 
of Helsinki and Good Clinical Practice and was approved by 
the Local Ethics Committee (EKSG 13/096). Between July 
2013 and June 2014, a total of 83 consecutive patients who 
had undergone unilateral ureteral stenting were included in 
the trial. Inclusion criteria were a unilateral ureteral stent 
inserted for treatment of uretero- or nephrolithiasis and 
informed consent. Exclusion criteria were previous ureteral 
stenting, pregnancy, bilateral ureteral stenting, obstruction 
due to malignancy, additional procedures or operations 
performed during stent indwelling time, and debilitating 
disease.
Percuflex ureteral stents (Boston Scientific, Natick, MA, 
USA) with a diameter of  6 French and lengths ranging 
from 26 to 30 cm were used, with the choice of  length 
depending on the surgeons’ estimate of  patient height 
and ureteral configuration by use of retrograde contrast 
ureteropyelography. Intravesical stent position was assessed 
by x-ray before stent removal and was classified into 3 
categories by using a perpendicular line through the middle 
of the gap of the symphysis pubis. In group A, the distal 
A B C
Fig. 1. Classification of intravesical stent length based on a perpendicular line through the middle of the gap of the symphysis pubis: loop completely 
ipsilateral (A), crossing midline (B), and completely contralateral (C).
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loop of the stent was completely ipsilateral, group B had 
loops crossing the perpendicular line, and group C consisted 
of patients with completely contralateral intravesical stent 
loops (Fig. 1). Patients were asked to complete the German 
version of the USSQ, rating the entire stent dwelling time, 
on the day before stent removal. Patients with incompletely 
answered questionnaires were excluded from the study. 
After primary data analysis, the immediate postoperative 
intravesical stent position was assessed retrospectively, as 
much as possible, to further verify the study results.
Categorical variables are reported as number (%) 
and were compared by using Fisher exact test, whereas 
continuous variables are reported as median (range) and 
were compared by using the Kruskal-Wallis test. Correlations 
between scores were estimated by using the Pearson 
correlation (with corresponding 95% confidence intervals). 
Correlations adjusted for various factors were estimated by 
using linear regression. A two-sided significance level of 0.05 
was used throughout. Holm’s [20] method (1979) was used to 
control for multiple testing. All analyses were performed 
in the R ver. 3.1.0 (R Foundation for Statistical Computing, 
Vienna, Austria).
RESULTS
Of the 83 patients enrolled in the study, six did not 
return the questionnaire, three were excluded owing to 
incomplete questionnaires, and one patient was excluded 
because the distal stent position was not clear on the x-ray. 
No cases of stent dislocation were observed and all of the 
remaining 73 patients had complete distal and proximal 
stent loops. Completely ipsilateral distal stent loops (group A) 
were present in 17.8% (n=13), whereas 27.4% (n=20) had distal 
loops tangential to the straight line through the symphysis 
(group B), and 54.8% (n=40) had completely contralateral 
loops (group C). Age, gender, intake of analgesics or alpha-
blockers, stent indication, and indwelling time did not differ 
significantly between the three groups. Demographics and 
clinical characteristics are summarized in Table 1.
Intravesical stent position did not significantly influence 
morbidity caused by ureteral stents. The median USSQ total 
score for all patients was 77.0 (range, 30–147). Patients with 
ipsilateral stents tended to have lower total scores with a 
median of 69.0 (range, 30–122) compared with 86.5 (range, 
30–122) for those with tangential stents and 77.0 (range, 
31–147) for those with contralateral stents. These differences 
were not statistically significant (p=0.35). There were also 
no significant differences between the USSQ subscores 
for urinary symptoms (p=0.80), body pain (p=0.80), general 
health (p=0.16), work performance (p=0.07), and additional 
problems (p=0.81) between the three groups. Only the USSQ 
subscore for sexual matters showed fewer symptoms in 
Table 1. Patient demographics and clinical characteristics
Variable All Group A Group B Group C
Intravesical stent position 73 (100) 13 (17.8) 20 (27.4) 40 (54.8)
Gender
    Women 17 (23.3) 3 (23.1) 7 (35) 7 (17.5)
    Men 56 (76.7) 10 (76.9) 13 (65) 33 (82.5)
Age (y) 52 (20–80) 54 (22–75) 51 (23–70) 52 (20–80)
Stent indwelling time (d) 30 (8–94) 26 (8–84) 27 (8–57) 32 (12–94)
Ureteral stent indication
    Preparation for secondary ureterorenoscopy 70 (95.9) 12 (92.3) 20 (100) 38 (95)
    After primary ureterorenoscopy 2 (2.7) - - 2 (5.0)
    Preparation for shock wave lithotripsy 1 (1.4) 1 (7.7) - -
Analgesics
    None 10 (13.7) 2 (15.4) 1 (5.0) 7 (17.5)
    Nonsteroidal anti-inflammatory drug 4 (5.5) 1 (7.7) 1 (5.0) 2 (5.0)
    Paracetamol 15 (20.6) 3 (23.1) 5 (25.0) 7 (17.5)
    Metamizole 7 (9.6) 1 (7.7) 3 (15.0) 3 (7.5)
    Combination of two of the above analgesics 37 (50.7) 6 (46.2) 10 (50.0) 21 (52.5)
Alpha-blocker
    None 59 (80.8) 10 (76.9) 17 (85.0) 32 (80.0)
    Tamsulosin 14 (19.2) 3 (23.1) 3 (15.0) 8 (20.0)
Values are presented as number (%) or median (range).
Group A, all ipsilateral; group B, tangential to symphysis pubis midline; group C, contralateral.
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patients with shorter indwelling stents (p=0.04) (Table 2).
No influence of stent position could be found for any of 
the USSQ single items relevant to stent length. This was 
shown by the absence of significant differences between 
groups for urinary frequency (represented by question U1, 
p=0.92), nocturia (U2, p=0.33), urgency (U3, p=0.40), urge 
incontinence (U4, p=0.39), dysuria (U7, p=0.53), incidence of 
hematuria (U8, p=0.81), intensity of hematuria (U9, p=0.41), 
pain while passing urine (P6, p=0.19), pain in the kidney 
area while passing urine (P7, p=0.96), difficulties with light 
physical activities (G1, p=0.08), and difficulties with heavy 
physical activities (G2, p=0.24) (Table 3). Moreover, no impact 
of stent position on the location of pain was found (Table 4).
X-rays performed immediately postoperatively could 
be analyzed retrospectively in 82.2% (n=60) of patients. We 
found that 43.0% (n=26) of these patients would have been 
assigned to a different group at this time, with 22 patients 
switching to a group with shorter distal stents and four 
patients assigned to a group with longer distal stents. Despite 
this, statistical analysis using this early assessment of stent 
position instead of stent position on the day before removal 
showed no influence on morbidity reflected by USSQ total 
scores, subscores, or single items (data not shown). With use 
of the initial stent position, not even the subscore for sexual 
matters was influenced by intravesical stent position (p=0.82).
DISCUSSION
The reasons for the morbidity caused by indwelling 
stents and their treatment and prevention have been 
investigated in several studies, the results of which can be 
summarized as follows: 
•	Oral	administration	of	alpha-blockers	[9]	or	antimuscarinics	
[10] can reduce discomfort caused by ureteral stents.
Table 2. Influence of stent length on total USSQ score and subscores
Variable Group No. NA Score, median (range) p-value
USSQ total score A 13 0 69.0 (30–122)
B 20 0 86.5 (30–122)
C 40 0 77.0 (31–147)
All 73 0 77.0 (30–147) 0.35
Urinary symptoms subscore A 13 0 28.0 (15–42)
B 20 0 28.5 (13–43)
C 40 0 29.5 (14–48)
All 73 0 29.0 (13–48) 0.80
Body pain subscore A 10 3 25.5 (11–35)
B 16 4 25.0 (11–30)
C 29 11 22.0 (11–34)
All 55 18 24.0 (11–35) 0.80
General health subscore A 13 0 13.0 (5–24)
B 20 0 16.0 (6–25)
C 40 0 13.5 (6–24)
All 73 0 14.0 (5–25) 0.16
Work performance  subscore A 5 8 3.0 (3–11)
B 15 5 9.0 (3–15)
C 25 15 7.0 (3–15)
All 45 28 7.0 (3–15) 0.07
Sexual matters subscore A 13 0 0 (0–11)
B 20 0 2.5 (0–11)
C 40 0 1.0 (0–11) 
All 73 0 1.0 (0–11) 0.04
Additional problems subscore A 13 0 5.0 (4–11)
B 20 0 6.0 (4–12)
C 40 0 6.5 (4–14)
All 73 0 6.0 (4–14) 0.81
USSQ, ureteral stent symptom questionnaire; NA, number of patients who denied having the symptom in question; Group A, all ipsilateral; group B, 
tangential to symphysis pubis midline; group C, contralateral.
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•	Despite	many	advances	in	stent	composition,	construction	
geometry, and design, the ideal stent has yet to be 
designed [21-23].
•	Drug-eluting	stents	seem	to	have	a	very	limited	effect	
[24] and do not play a role in clinical routine.
•	Positioning	of	the	stent’s	proximal	end	[11]	and	stent	
Table 3. Influence of stent length on USSQ single items
Variable Group No. NA Score, median (range) p-value 
Diuria (U1) A 13 0 3.0 (1–5)
B 20 0 3.0 (2–5)
C 40 0 3.0 (1–5)
All 73 0 3.0 (1–5) 0.92
Nocturia (U2) A 13 0 3.0 (2–4)
B 20 0 3.0 (1–5)
C 40 0 3.0 (1–5)
All 73 0 3.0 (1–5) 0.33
Urgency (U3) A 13 0 2.0 (1–4)
B 20 0 2.0 (1–5)
C 40 0 2.5 (1–6)
All 73 0 2.0 (1–6) 0.40
Urge-incontinence (U4) A 13 0 1.0 (1–3)
B 20 0 1.0 (1–4)
C 40 0 1.0 (1–4)
All 73 0 1.0 (1–4) 0.39
Dysuria (U7) A 13 0 2.0 (1–5)
B 20 0 3.0 (1–5)
C 40 0 3.0 (1–5)
All 73 0 3.0 (1–5) 0.53
Incidence of hematuria (U8) A 13 0 3.0 (1–5)
B 20 0 2.0 (1–5)
C 40 0 2.0 (1–5)
All 73 0 2.0 (1–5) 0.81
Extent of hematuria (U9) A 13 0 2.0 (1–3)
B 20 0 2.0 (1–3)
C 40 0 2.0 (1–4)
All 73 0 2.0 (1–4) 0.41
Pain while passing urine (P6) A 10 3 4.0 (1–5)
B 16 4 3.0 (1–5)
C 30 10 4.0 (2–5)
All 56 17 4.0 (1–5) 0.19
Kidney pain while passing urine (P7) A 10 3 2.0 (1–2)
B 16 4 2.0 (1–2)
C 29 11 2.0 (1–2)
All 55 18 2.0 (1–2) 0.96
Difficulties with light physical activities (G1) A 13 0 1.0 (0–3)
B 20 0 2.5 (0–4)
C 40 0 2.0 (1–4)
All 73 0 2.0 (0–4) 0.08
Difficulties with heavy physical activities (G2) A 13 0 1.0 (0–4)
B 20 0 3.0 (0–4)
C 40 0 2.0 (0–4)
All 73 0 2.0 (0–4) 0.24
USSQ, ureteral stent symptom questionnaire; NA, number of patients who denied having the symptom in question; Group A, all ipsilat-eral; group 
B, tangential to symphysis pubis midline; group C, contralateral.
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diameter [12-14] do not seem to influence morbidity.
However, previous findings regarding the possible effect 
of intravesical stent position are ambiguous.
The present study examined the influence of intravesical 
stent position on problems caused by ureteral stents by use 
of a questionnaire designed specifically to assess ureteral 
stent symptoms (the USSQ). Assessment of  distal stent 
position and stent-related symptoms was deliberately 
performed at the end of  stent indwelling time, because 
we believed that this would take into account the stent’s 
predominant position better than early postoperative 
assessment.
We did not find a significant impact of intravesical stent 
position on typical complaints associated with indwelling 
ureteral stents. Only the subscore for sexual matters showed 
fewer symptoms in patients with shorter intravesical stents 
(p=0.04). This might be of questionable relevance, however, 
taking into account that with the use of the initial stent 
position, the subscore for sexual matters was not influenced 
by intravesical stent length (p=0.82) and, moreover, that 
there was no significant difference between the groups 
regarding difficulties with light physical activities (G1) and 
difficulties with heavy physical activities (G2).
The pathogenesis of stent-related symptoms is generally 
divided into two issues. The first is vesicoureteric reflux, 
which typically causes flank pain aggravated by micturition. 
It appears logical that this problem is not influenced by 
intravesical stent position as reflected by question P7 
(occurrence of flank pain during micturition). The second 
issue is that most symptoms observed are ascribed to the 
intravesical part of  the stent as a foreign body causing 
irritative voiding problems and pain in the urinary bladder, 
A B C D
Fig. 2. Study patient treated by shock wave 
lithotripsy (SWL) secondary to stenting 
with pushback. X-rays performed before 
and after treatment show high variability 
of distal stent location. (A) Intraoperative 
x-ray. (B) One day after stent insertion. (C) 
Three weeks after insertion (before SWL). 
(D) Three weeks after SWL (before stent 
removal).
Table 4. Influence of stent length on pain location
Body part Group A Group B Group C All p-value 
Lateral flank 0.46
    No pain 7 (53.9) 13 (65.0) 29 (72.5) 49 (67.1)
    Pain 6 (46.1) 7 (35.0) 11 (27.5) 24 (32.9)
Dorsal flank 0.16
    No pain 6 (46.1) 8 (40.0) 26 (65.0) 40 (54.8)
    Pain 7 (53.9) 12 (60.0) 14 (35.0) 33 (45.2)
Lower abdomen 0.72
    No pain 9 (69.2) 11 (55.0) 26 (65.0) 46 (63.0)
    Pain 4 (30.8) 9 (45.0) 14 (35.0) 27 (37.0)
Groin 0.55
    No pain 10 (76.9) 15 (75.0) 25 (62.5) 50 (68.5)
    Pain 3 (23.1) 5 (25.0) 15 (37.5) 23 (31.5)
Genitalia 0.22
    No pain 13 (100) 17 (85.0) 32 (80.0) 62 (84.9)
    Pain 0 (0) 3 (15.0) 8 (20.0) 11 (15.1)
Values are presented as number (%).
Group A, all ipsilateral; group B, tangential to symphysis pubis midline; group C, contralateral.
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often radiating to the genitalia. In this regard, longer 
intravesical stents might cause more problems because 
they may cause more irritation to the bladder neck and 
the trigone, which are well known to comprise most of the 
sensory afferents in the urinary bladder [25]. In our study, 
however, no differences in extent or site of pain were found 
between the different groups. Moreover, equal distribution 
of diuria and nocturia (reflected by questions U1 and U2) 
and frequency and severity of gross hematuria (U8 and U9) 
seem to argue against greater irritation caused by longer 
intravesical stents.
Studies on this topic performed so far show conflicting 
results. In this regard, the study by Giannarini et al. [15] may 
be the most important because it was prospective and used a 
specific questionnaire (USSQ) with assessment of symptoms 
and stent position on days 7 and 28 after placement. A 
reason for the differing results with our study might be the 
different time points at which stent position and symptoms 
were assessed, i.e., on the day before stent removal. For this 
reason, we analyzed the x-rays that had been performed 
immediately after stent insertion and found that on this 
basis as many as 43% of patients would have been assigned 
to a different group, indicating a certain flexibility of 
stent location. Other reasons for the differences between 
results may be different exclusion criteria. Our study did 
not exclude patients with LUTS with or without medical 
treatment, because LUTS are highly prevalent in the 
normal population and patients affected may be especially 
susceptible to stent-related symptoms. Unfortunately, we 
did not assess the prevalence of LUTS in our study groups. 
Moreover, to improve the accuracy of assessing intravesical 
stent length by x-ray, we decided to categorize patients into 
three instead of two groups. However, analysis of our data 
in only two groups showed the same results. The results 
of the study by Giannarini et al. [15] may also have been 
influenced by not being corrected for multiple testing, which 
we did in our study. As in our study, Giannarini et al. [15] 
did not randomize for distal stent positioning and they used 
the same type of stents, although somewhat shorter (24–28 
cm instead of 26–30 cm). In both studies, bladder filling at 
the time of x-ray was not assessed. 
There may be a fundamental problem of using intravesical 
stent length categorized by x-ray as a predictor of morbidity: 
it varies and may have more the nature of a snapshot than 
a fixed state. Furthermore, the influence of bladder volume 
on stent position has never been evaluated systemically. 
Moreover, stents can adopt different positions as the body 
moves and changes position, as demonstrated in a study by 
Chew et al. [26]. This assumption was also strengthened by a 
post hoc analysis of the study by Giannarini et al. [15], which 
showed no significant correlation between stent location and 
distal loop location. This is also well illustrated by our study 
patient who underwent shock wave lithotripsy after stenting 
and thus had several x-rays showing a high variability of 
distal stent location (Fig. 2).
Moreover, depending on the configuration of the bladder 
neck and intramural ureter, distal stent loops with an 
apparent initial ideal length may interfere more with the 
bladder neck than longer stents that may not be in contact 
with the bladder neck at all. In line with this, very different 
intravesical stent alignments were found between women, 
in whom pelvic floor prolapse might play an important 
role, and men, in whom prostate size, for example, might 
influence irritation caused by the stent. Both may not only 
influence the degree of irritation to the bladder wall and 
neck, but also affect assignment to groups as discussed 
above. 
Our study had limitations. Intravesical stent position was 
assessed only on the day of stent removal. Thus, analysis of 
the stent position directly after the intervention had to be 
performed retrospectively and there was no assessment of 
symptoms at this time. We believed that this might show the 
stent’s predominant position better than early postoperative 
assessment, because stents might not adopt a “permanent” 
position before the patient is mobilized after surgery. This 
time of assessment was also chosen for practical reasons: 
patients had an appointment for secondary stone treatment 
then and this offered an overview of all symptoms they had 
experienced during the whole stent indwelling time. Also, 
symptoms were not assessed after stent removal, which 
would have allowed a better causal link between symptoms 
and the indwelling stent. A further limitation is that stent 
insertion was not randomized, because randomization 
would have necessitated extensive manipulation, which 
may also have influenced symptoms. The German version 
of the USSQ is not validated. However, the USSQ is a well-
established questionnaire for the assessment of symptoms 
associated with indwelling ureteral stents that has been 
validated in several languages. We used the same translation 
process as for all other translations, and the German version 
is at present undergoing validation (data not yet published). 
CONCLUSIONS 
Intravesical stent position did not appear to influence 
morbidity caused by ureteral stents in our study and 
focusing on length does not appear to be a promising 
approach to improving stent-related symptoms. Assessment 
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of stent position by x-ray may be a misleading simplification 
of the true situation. An appropriate stent length is certainly 
required, if  only to avoid stent dislocation, but extensive 
calculations using formulae or based on imaging do not 
seem to be reasonable. Stents that seem a little too long after 
insertion can generally be left, thus avoiding further time-
consuming manipulation. Costly stock holding of various 
stent sizes to obtain the perfect length is not necessary.
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